选择性雌激素受体降解剂 (SERD) amcenestrant 治疗乳腺癌,未能达到主要终点

2022-03-14 Allan MedSci原创

赛诺菲近日宣布对其实验性选择性雌激素受体降解剂 (SERD) amcenestrant 的 II 期研究未能达到其改善某些乳腺癌患者的无进展生存期 (PFS) 的主要终点。

雌激素受体(ER)在ER阳性乳腺癌的基因转录和增殖中起重要作用。ER的选择性调节已超过30年来一直是这种特定类型乳腺癌的治疗目标。选择性雌激素受体调节剂(SERMs)和芳香化酶抑制剂(AIs)已被证明是ER阳性乳腺癌的有效治疗方法。不幸的是,3–5年后,有30–50%的ER阳性肿瘤对SERM / AI治疗产生抗药性。

雌激素受体(ER)阳性、人表皮生长因子受体2(HER2)阴性乳腺癌是最多发的乳腺癌类型,占50岁以下女性乳腺癌病例的65%和50岁及以上女性乳腺癌病例的75%。雌激素与ER结合,刺激受体调节下的转录,进而促进肿瘤细胞的生长和增殖。ER阳性乳腺癌具有异质性。不同肿瘤在以下方面存在差异:ER数量水平、孕激素受体(PR)表达(由ER驱动)、组织学分级、增殖程度(通过Ki-67标志或其他指标衡量)、基因表达模式及基因组改变的类型和频率。对ER阳性乳腺癌采取的激素疗法可减少雌激素生成、中断ER信号传导、降解ER或者改变ER调节下的信号传导或增殖通路。

赛诺菲近日宣布对其实验性选择性雌激素受体降解剂 (SERD) amcenestrant 的 II 期研究未能达到其改善某些乳腺癌患者的无进展生存期 (PFS) 的主要终点。赛诺菲研发主管 John Reed 表示:“尽管结果令人失望,但我们将继续研究 amcenestrant 对具有不同肿瘤特征的早期乳腺癌患者的有效性”。

AMERA-3 试验评估了口服 amcenestrant 作为单一疗法与医生选择的内分泌治疗相比,在激素治疗期间或之后进展的局部晚期或转移性雌激素受体阳性 (ER+)/HER2 阴性乳腺癌患者的有效性。结果显示,试验中没有发现新的安全信号。

 

原始出处:

https://firstwordpharma.com/story/5524831

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1996995, encodeId=a46119969957f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Tue Aug 16 14:08:16 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051761, encodeId=61512051e61f8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Sep 26 00:08:16 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657618, encodeId=5e27165e6187e, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 03:08:16 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922996, encodeId=5a36192299613, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Jan 06 03:08:16 CST 2023, time=2023-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503503, encodeId=1a5b15035035d, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Wed Mar 16 14:08:16 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202839, encodeId=4a781202839e3, content=好东西,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0be2111725, createdName=萌宝嘟嘟, createdTime=Tue Mar 15 19:01:46 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202628, encodeId=aa421202628ca, content=好好学, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Mon Mar 14 23:32:19 CST 2022, time=2022-03-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1996995, encodeId=a46119969957f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Tue Aug 16 14:08:16 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051761, encodeId=61512051e61f8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Sep 26 00:08:16 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657618, encodeId=5e27165e6187e, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 03:08:16 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922996, encodeId=5a36192299613, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Jan 06 03:08:16 CST 2023, time=2023-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503503, encodeId=1a5b15035035d, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Wed Mar 16 14:08:16 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202839, encodeId=4a781202839e3, content=好东西,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0be2111725, createdName=萌宝嘟嘟, createdTime=Tue Mar 15 19:01:46 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202628, encodeId=aa421202628ca, content=好好学, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Mon Mar 14 23:32:19 CST 2022, time=2022-03-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1996995, encodeId=a46119969957f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Tue Aug 16 14:08:16 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051761, encodeId=61512051e61f8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Sep 26 00:08:16 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657618, encodeId=5e27165e6187e, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 03:08:16 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922996, encodeId=5a36192299613, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Jan 06 03:08:16 CST 2023, time=2023-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503503, encodeId=1a5b15035035d, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Wed Mar 16 14:08:16 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202839, encodeId=4a781202839e3, content=好东西,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0be2111725, createdName=萌宝嘟嘟, createdTime=Tue Mar 15 19:01:46 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202628, encodeId=aa421202628ca, content=好好学, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Mon Mar 14 23:32:19 CST 2022, time=2022-03-14, status=1, ipAttribution=)]
    2022-09-25 bsmagic9140
  4. [GetPortalCommentsPageByObjectIdResponse(id=1996995, encodeId=a46119969957f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Tue Aug 16 14:08:16 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051761, encodeId=61512051e61f8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Sep 26 00:08:16 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657618, encodeId=5e27165e6187e, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 03:08:16 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922996, encodeId=5a36192299613, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Jan 06 03:08:16 CST 2023, time=2023-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503503, encodeId=1a5b15035035d, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Wed Mar 16 14:08:16 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202839, encodeId=4a781202839e3, content=好东西,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0be2111725, createdName=萌宝嘟嘟, createdTime=Tue Mar 15 19:01:46 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202628, encodeId=aa421202628ca, content=好好学, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Mon Mar 14 23:32:19 CST 2022, time=2022-03-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1996995, encodeId=a46119969957f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Tue Aug 16 14:08:16 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051761, encodeId=61512051e61f8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Sep 26 00:08:16 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657618, encodeId=5e27165e6187e, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 03:08:16 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922996, encodeId=5a36192299613, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Jan 06 03:08:16 CST 2023, time=2023-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503503, encodeId=1a5b15035035d, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Wed Mar 16 14:08:16 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202839, encodeId=4a781202839e3, content=好东西,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0be2111725, createdName=萌宝嘟嘟, createdTime=Tue Mar 15 19:01:46 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202628, encodeId=aa421202628ca, content=好好学, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Mon Mar 14 23:32:19 CST 2022, time=2022-03-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1996995, encodeId=a46119969957f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Tue Aug 16 14:08:16 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051761, encodeId=61512051e61f8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Sep 26 00:08:16 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657618, encodeId=5e27165e6187e, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 03:08:16 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922996, encodeId=5a36192299613, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Jan 06 03:08:16 CST 2023, time=2023-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503503, encodeId=1a5b15035035d, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Wed Mar 16 14:08:16 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202839, encodeId=4a781202839e3, content=好东西,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0be2111725, createdName=萌宝嘟嘟, createdTime=Tue Mar 15 19:01:46 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202628, encodeId=aa421202628ca, content=好好学, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Mon Mar 14 23:32:19 CST 2022, time=2022-03-14, status=1, ipAttribution=)]
    2022-03-15 萌宝嘟嘟

    好东西,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1996995, encodeId=a46119969957f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Tue Aug 16 14:08:16 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051761, encodeId=61512051e61f8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Sep 26 00:08:16 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657618, encodeId=5e27165e6187e, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 03:08:16 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922996, encodeId=5a36192299613, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Jan 06 03:08:16 CST 2023, time=2023-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503503, encodeId=1a5b15035035d, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Wed Mar 16 14:08:16 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202839, encodeId=4a781202839e3, content=好东西,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0be2111725, createdName=萌宝嘟嘟, createdTime=Tue Mar 15 19:01:46 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202628, encodeId=aa421202628ca, content=好好学, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Mon Mar 14 23:32:19 CST 2022, time=2022-03-14, status=1, ipAttribution=)]
    2022-03-14 liuyingying35

    好好学

    0

相关资讯

JEADV:芳香酶抑制剂治疗乳腺癌患者额部纤维性脱发2例

脱发是已知的芳香化酶抑制剂的潜在副作用,本文报告了两例服用阿那曲唑辅助治疗的绝经后激素受体(雌激素和孕酮)阳性的乳腺癌患者发展为额叶纤维性脱发的病例。

你的坏情绪都表现在乳房上,这几个身体信号应警惕!

乳房是情绪的“靶向器官”,就像一面镜子,情绪上的任何波动都有可能被它直接反映出来。

European Radiology:DW MRI在预测乳腺癌新辅助化疗早期反应中的价值

目前,新辅助化疗(NAC)已广泛用于乳腺癌的治疗。新辅助化疗通常应用于患有局部晚期乳腺癌和炎症性乳腺癌的患者中国,可降低肿瘤的分期以便进行保乳手术。

JAMA Oncol:仿制药HD201在ERBB2阳性乳腺癌中的疗效堪比曲妥珠单抗!

曲妥珠单抗的使用改变了ERBB2阳性乳腺癌的治疗和预后。但是,曲妥珠单抗的高昂费用限制了很多患者的使用。通过开发类似曲妥珠单抗的生物仿制药或有助于满足大量乳腺癌患者的需求。

Cell子刊:复旦团队发现,细菌是“最凶乳腺癌”治疗的新希望

研究显示,微生物代谢产物TMAO有望成为三阴性乳腺癌临床免疫治疗的新策略,助推免疫治疗。

European Radiology:放射组学,为乳腺癌患者的术前评估提供了“病理级”指导!

乳腺癌已成为全世界范围内最常见的癌症之一,也是女性癌症相关死亡的主要原因。在这些患者中,导致死亡的主要原因是远处转移而肺原发肿瘤。

拓展阅读

徐兵河院士:乳腺癌临床研究的进展与未来

在2024南北汇暨第六届中华乳腺肿瘤论坛上,中国医学科学院肿瘤医院徐兵河院士分享了学术报告——《乳腺癌临床研究的进展与未来》,重点分享了其所在团队取得的研究成果。

《新英格兰医学》最新报道,瑞博西尼可降低25%的乳腺癌复发!

为了降低乳腺癌的术后复发风险,研究者开始考虑将一款细胞周期蛋白依赖激酶4/6的抑制剂加入,这类药物主要是用来调控细胞增殖,比较为大家所知的就是瑞博西尼。

论文解读|Yang Liu/Pan Zheng教授团队揭示创新型RNA递送平台在癌症治疗中的前景

这项研究展示了一个新型的递送平台,它使用镁来形成纳米颗粒,实现了有针对性、高效和安全的RNA递送,对乳腺癌的潜在治疗效益也得到了证明。

Lancet Oncol | coopERA Breast Cancer研究:新辅助哌柏西利加giredestrant或阿那曲唑治疗雌激素受体阳性、HER2阴性的乳腺癌

该研究旨在比较哌柏西利加giredestrant或阿那曲唑治疗雌激素受体阳性、HER2阴性的乳腺癌的疗效和安全性,giredestrant较阿那曲唑能更有效地抑制肿瘤增殖且安全可控。

European Radiology:MR在预测乳腺癌新辅助化疗病理完全缓解中的附加价值

MRI是NAC治疗前分期和肿瘤反应监测的首选方法,并可以使用形态学和功能学参数 (如弥散加权成像)来提高NAC治疗后肿瘤反应的预测。

【专家访谈】靶向药物拓展了HR+/HER2-转移性乳腺癌领域的治疗

在演讲中,Stringer-Reasor重点介绍了针对HR+/HER2-转移性乳腺癌患者的新型疗法和新兴疗法,解释了目前针对CDK4/6抑制剂一线治疗取得进展的患者能否继续使用CDK4/6抑制剂治疗。